Aduro Biotech Enters Into Definitive Agreement to Acquire Premier Antibody Portfolio and Engineering Capabilities Through Purchase of BioNovion, EUR$14.5 Cash & EUR$14.4M Aduro Stock
September 24, 2015 at 16:01 PM EDT
Aduro Biotech, Inc. (Nasdaq: ADRO) and BioNovion Holding B.V. announced today that they have entered into a definitive agreement for ...
